{"denoms":[{"counts":[{"groupId":"BG000","value":"4"}],"units":"Participants"}],"groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"BG000","title":"Elranatamab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.03","value":"64.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"comment":"Data cannot be reported due to low enrollment in one category and would lead to risk of re-identification of participants.","groupId":"BG000","value":"NA"}],"title":"Female"},{"measurements":[{"comment":"Data cannot be reported due to low enrollment in one category and would lead to risk of re-identification of participants.","groupId":"BG000","value":"NA"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Asian"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Safety Analysis Set (SAS) included all enrolled participants who received at least 1 dose of study intervention."}